Mohali Police Bust Unit Producing Fake Medicine

Mohali:  Mohali police on Friday busted a manufacturing unit that produced fake and banned medicines.

Deputy superintendent of police (DSP) Harsimran Singh Bal said three accused have been arrested and a large quantity of banned medicines being manufactured at the unit has been recovered.

The DSP said acting on a tip-off, a police team raided MK Tech park in IT City and arrested Chinda and Harpreet Singh, residents of Pinjore in Panchkula, and Sumit Kumar, a resident of Nirjapur.

The DSP said the police recovered banned medicine Clave M 1475 tablets, Telma M 11865 tablets, Tryprin 20 kg, loose tablets 2.5kg and packaging material from the unit.

The accused have been sent to a two-day police remand. A case has been registered under relevant sections of the Bharatiya Nyaya Sanhita at IT City police station.

Related Posts

  • Pharma
  • June 17, 2025
  • 91 views
Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Bengaluru-based biopharmaceutical firm Biocon on Monday launched a qualified institutions placement (QIP) to raise Rs 4,500 crore. As part of the offering, the firm will issue up to 139 million…

  • Pharma
  • June 17, 2025
  • 96 views
Zydus Healthcare appoints Swati Dalal MD

Zydus Lifesciences Ltd on Monday announced the appointment of Swati Dalal as an additional director and Managing Director of its wholly-owned arm Zydus Healthcare Ltd. The board of Zydus Healthcare…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Zydus Healthcare appoints Swati Dalal MD

Zydus Healthcare appoints Swati Dalal MD

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

Natco API plant gets one observation from FDA

Natco API plant gets one observation from FDA